Literature DB >> 30459211

Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Rikke Stagaard1,2,3, Carsten Dan Ley2, Kasper Almholt2, Lisbeth Høier Olsen3, Tom Knudsen2, Matthew J Flick1.   

Abstract

Plasminogen deficiency is associated with severely compromised fibrinolysis and extravascular deposition of fibrin. In contrast, coagulation factor VIII (FVIII) deficiency leads to prolonged and excessive bleeding. Based on opposing biological functions of plasminogen and FVIII deficiencies, we hypothesized that genetic elimination of FVIII would alleviate the systemic formation of fibrin deposits associated with plasminogen deficiency and, in turn, elimination of plasminogen would limit bleeding symptoms associated with FVIII deficiency. Mice with single and combined deficiencies of FVIII (F8-/-) and plasminogen (Plg-/-) were evaluated for phenotypic characteristics of plasminogen deficiency, including wasting disease, shortened lifespan, rectal prolapse, and multiorgan fibrin deposition. Conversely, to specifically examine the role of plasmin-mediated fibrinolysis on bleeding caused by FVIII deficiency, F8-/- and F8-/-/Plg-/- mice were subjected to a bleeding challenge. Mice with a combined deficiency in FVIII and plasminogen displayed no phenotypic differences relative to mice with single FVIII or plasminogen deficiency. Plg-/- and F8-/-/Plg-/- mice exhibited the same penetrance and severity of wasting disease, rectal prolapse, extravascular fibrin deposits, and reduced viability. Furthermore, following a tail vein-bleeding challenge, no significant differences in bleeding times or total blood loss could be detected between F8-/- and F8-/-/Plg-/- mice. Moreover, F8-/- and F8-/-/Plg-/- mice responded similarly to recombinant FVIII (rFVIII) therapy. In summary, the pathological phenotype of Plg-/- mice developed independently of FVIII-dependent coagulation, and elimination of plasmin-driven fibrinolysis did not play a significant role in a nonmucosal bleeding model in hemophilia A mice.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30459211      PMCID: PMC6258924          DOI: 10.1182/bloodadvances.2018024851

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  66 in total

1.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Multimodal blood loss prevention approach including intra-articular tranexamic acid in primary total knee arthroplasty for patients with severe haemophilia A.

Authors:  E C Rodriguez-Merchan; J A Romero-Garrido; P Gomez-Cardero
Journal:  Haemophilia       Date:  2016-05-26       Impact factor: 4.287

3.  Hemostatic factors in rabbit limb lymph: relationship to mechanisms regulating extravascular coagulation.

Authors:  D T Le; P Borgs; T W Toneff; M H Witte; S I Rapaport
Journal:  Am J Physiol       Date:  1998-03

4.  Tissue-type plasminogen activator deficiency exacerbates arthritis.

Authors:  Y H Yang; P Carmeliet; J A Hamilton
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

5.  Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.

Authors:  T H Bugge; M J Flick; C C Daugherty; J L Degen
Journal:  Genes Dev       Date:  1995-04-01       Impact factor: 11.361

Review 6.  Plasminogen deficiency.

Authors:  R Mehta; A D Shapiro
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

7.  Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors.

Authors:  K Ghosh; S Shetty; F Jijina; D Mohanty
Journal:  Haemophilia       Date:  2004-01       Impact factor: 4.287

8.  Physiological consequences of loss of plasminogen activator gene function in mice.

Authors:  P Carmeliet; L Schoonjans; L Kieckens; B Ream; J Degen; R Bronson; R De Vos; J J van den Oord; D Collen; R C Mulligan
Journal:  Nature       Date:  1994-03-31       Impact factor: 49.962

9.  Hepatocyte tissue factor activates the coagulation cascade in mice.

Authors:  Bradley P Sullivan; Anna K Kopec; Nikita Joshi; Holly Cline; Juliette A Brown; Stephanie C Bishop; Karen M Kassel; Cheryl Rockwell; Nigel Mackman; James P Luyendyk
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

10.  Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis in mice.

Authors:  Heather A Cole; Tetsuro Ohba; Jeffry S Nyman; Haro Hirotaka; Justin M M Cates; Matthew J Flick; Jay L Degen; Jonathan G Schoenecker
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

View more
  3 in total

1.  Hypofibrinogenemia with preserved hemostasis and protection from thrombosis in mice with an Fga truncation mutation.

Authors:  Woosuk S Hur; David S Paul; Emma G Bouck; Oscar A Negrón; Jean-Marie Mwiza; Lauren G Poole; Holly M Cline-Fedewa; Emily G Clark; Lih Jiin Juang; Jerry Leung; Christian J Kastrup; Tatiana P Ugarova; Alisa S Wolberg; James P Luyendyk; Wolfgang Bergmeier; Matthew J Flick
Journal:  Blood       Date:  2022-03-03       Impact factor: 22.113

2.  Bleeding is increased in amyloid precursor protein knockout mouse.

Authors:  Nima Mazinani; Amy W Strilchuk; James R Baylis; Woosuk S Hur; Wilfred A Jefferies; Christian J Kastrup
Journal:  Res Pract Thromb Haemost       Date:  2020-06-14

3.  Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.

Authors:  Henrik Andersen; Maria Høj Hansen; Kristian B Buhl; Mette Stæhr; Ulla G Friis; Camilla Enggaard; Shanya Supramaniyam; Ida K Lund; Per Svenningsen; Pernille B L Hansen; Boye L Jensen
Journal:  J Am Heart Assoc       Date:  2020-11-20       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.